6201 gausroid presentation gitanjali avhad & umesh soni
DESCRIPTION
This is an NDA submission presentation in class setting showing a drug submission to treat hypothyroidism.TRANSCRIPT
1
Gaus Pharma
Course: RGA 6201
Instructor: Dr. Anupama Gaur
Gaus Pharma Overview
Hypothyroidism
Market Scenario
Gausroid
Regulatory plan
Post approval strategy
2
“Gaus” means “Foolish Person”.
US based Pharmaceutical Company
Located in Boston
700 Employees
40 Veteran Regulatory Employees.
Filing NDA for Gausroid
3
Deficiency of Thyroid
Hormone.
Acquired or Congenital.
2-5% World Population
3.7% in U.S Population
(~Ten million).
Women > Men
More risk in Elders.
4
Levothyroxine Sodium e.g.
*Synthroid(Abbott)-$520 million
*Levoxyl (Pfizer)- $15.4 million
Problems:
-Effect on bone density
-Unstable
-Potency problem
-Costly
5
Levothyroxine Calcium.
Oral Replacement Therapy
New Improved Formulation:
-Restores Bone Mineral Density
-Lesser Adverse Event
-More Stable
-More Potent
-Economical
6
7
IND Application Filed in eCTD
NDA Application Filed in eCTD
Label Expansion Strategies
GAUSROID
DEVELOPMENT
8
Pharmacology
Toxicology
Single-dose toxicity
Repeat –dose toxicity
Genotoxicity
Carcinogenicity
Immunotoxicity
Reproductive and developmental toxicity
• Primary Pharmacodynamics
• Secondary Pharmacodynamics
• Safety Pharmacology
Pharmacodynamics
•Absorption,
•Distribution,
•Metabolism
• Excretion
Pharmacokinetics
*CFR Title 21 part 58 (GLP)
*ICH Guidelines: Safety, Quality, MultidisciplinaryNon
Clinical studies
9
Gausroid CMC Complies with:
CFR Title 21 part 211 (cGMP)
ICH Guidelines
CMC Contains:
Drug Substance and Drug Product, ICH Q6A
Stability, ICH Q1A (R2)
Manufacturing Process Development
Quality, Identity and Purity ICH Q6A
10
Pre IND:
-Type B Meeting as per 21 CFR 312.82.
Purpose:
To Discuss Scope and Design of Phase I.
To Investigate Shortcomings.
eCTD Format through FDA’s Electronic
Submission Gateway.
11
Clinical Trials After IND Approval
Three phases Studies
Multi Centers Clinical Trials in US
Randomized, Double-Blinded,
Placebo Concurrent trials.
Conducted on Adults
Age 21 yrs-75 yrs.
ICH E6 guidelines: GCP
12
Clinical Studies
Conducted on 50 Healthy Volunteers
Purpose: To Ensure Safety
*To Evaluate Pharmacological Action.
*To Determine Side EffectsConducted on 600 Adult Patients
Purpose: To Start Efficacy Studies and
selecting Dose for Phase III
*To Evaluate Effectiveness for Proposed
Indication
*Short Term Side Effects and RisksOn 2500 Patients with 40 weeks follow up
Purpose: To Ensure Efficacy.
*To Evaluate Benefit to Risk Ratio.
*To Collect additional data for Establishing
Physician Labeling.
13
eCTD via Electronic Submission Gateway:
-FDA Form 356h
-FDA 3397: User Fee Cover Sheet
Payment of User Fees by PDUFA IV
$1,841,500 via Wire Transfer to U.S. bank in
St. Louis.
Submission of12 copies of Final Printed
Label with NDA.
Establishment:
-Risk Evaluation and Mitigation Strategies
-RiskMAPs
REMS Includes:
Medication Guide
Package Insert
Communication Plan for HCP’s.
14
Post Marketing Plans:
Clinical Studies for Secondary Indications.
Pediatric Population
Launching Dosage Strengths
Free Patients Counseling
Promotional Campaign
Committed for Safety Reporting
15
Thank You for Your
Attention
16
17